Reports for APOTEX INC
Company Name APOTEX INC |
||
---|---|---|
Totals |
||
Shortage reports |
3367 |
|
Actual shortage: | 219 (7%) | |
Anticipated shortage: | 0 (0%) | |
Avoided shortage: | 10 (0%) | |
Resolved: | 3138 (93%) | |
Discontinuation Reports |
365 |
|
To be discontinued: | 24 (7%) | |
Discontinued: | 341 (93%) | |
Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
68 (28%) |
Shortage reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-GLICLAZIDE | 80MG | TABLET | Actual shortage | 2025-04-04 | 2025-04-25 | 254165 |
APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2022-01-28 | 2022-02-08 | 153780 |
APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2022-12-16 | 2022-12-23 | 178760 |
APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2023-04-21 | 2023-06-29 | 189988 |
APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2024-01-26 | 2024-03-15 | 217487 |
APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2024-03-01 | 2024-03-15 | 221093 |
APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2024-04-05 | 2024-06-07 | 224583 |
APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2024-04-19 | 2024-06-07 | 225799 |
APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2020-09-02 | 2020-09-14 | 123561 |
APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2018-05-01 | 2018-09-11 | 47680 |
APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2017-10-17 | 2018-05-22 | 26159 |
APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2020-02-13 | 2020-04-14 | 105997 |
APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2024-06-20 | 2024-08-02 | 231033 |
APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2024-09-27 | 2024-11-22 | 238838 |
APO-GLICLAZIDE MR | 60MG | TABLET (EXTENDED-RELEASE) | Resolved | 2024-06-27 | 2024-08-07 | 231493 |
APO-GLICLAZIDE MR | 30MG | TABLET (EXTENDED-RELEASE) | Resolved | 2024-08-29 | 2024-11-01 | 236261 |
APO-GLICLAZIDE MR | 60MG | TABLET (EXTENDED-RELEASE) | Resolved | 2024-10-04 | 2025-01-10 | 239373 |
APO-GLICLAZIDE MR | 60MG | TABLET (EXTENDED-RELEASE) | Resolved | 2024-01-26 | 2024-05-31 | 217481 |
APO-GLICLAZIDE MR | 30MG | TABLET (EXTENDED-RELEASE) | Resolved | 2024-04-19 | 2024-06-21 | 225793 |
APO-GLICLAZIDE MR | 30MG | TABLET (EXTENDED-RELEASE) | Resolved | 2025-01-30 | 2025-03-28 | 249074 |
Discontinuation reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO PEN VK | Discontinued | 2019-03-08 | 2019-03-08 | 78141 | ||
APO PEN VK | Discontinued | 2019-03-08 | 2019-03-08 | 78144 | ||
APO PREDNISONE TAB 1MG USP | 1MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1056 |
APO PREDNISONE TAB 5MG | 5MG | TABLET | Discontinued | 2018-09-08 | 2018-12-28 | 60699 |
APO TRIAZIDE | 50MG 25MG | TABLET | Discontinued | 2018-09-08 | 2019-02-13 | 60837 |
APO-ABACAVIR-LAMIVUDINE-ZIDOVUDINE | 300MG 150MG 300MG | TABLET | Discontinued | 2022-12-12 | 2022-12-12 | 177953 |
APO-ACEBUTOLOL | 400MG | TABLET | Discontinued | 2017-03-31 | 2018-02-05 | 4965 |
APO-ACETAMINOPHEN CAPLETS 500MG | 500MG | TABLET | Discontinued | 2018-09-07 | 2018-09-08 | 60157 |
APO-ALENDRONATE | 5MG | TABLET | Discontinued | 2019-01-03 | 2019-12-21 | 71023 |
APO-ALENDRONATE | 10MG | TABLET | To be discontinued | 2019-01-03 | 2019-12-20 | 71026 |
APO-ALENDRONATE | 10MG | TABLET | To be discontinued | 2018-09-07 | 2019-12-20 | 60163 |
APO-ALMOTRIPTAN | Discontinued | 2019-05-13 | 2019-05-13 | 83971 | ||
APO-ALMOTRIPTAN | Discontinued | 2019-05-13 | 2019-05-13 | 83976 | ||
APO-AMITRIPTYLINE | 10MG | TABLET | Discontinued | 2025-01-10 | 2025-01-11 | 247462 |
APO-AMITRIPTYLINE | 10MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71348 |
APO-AMITRIPTYLINE | 75MG | TABLET | To be discontinued | 2025-01-10 | 2025-01-10 | 247472 |
APO-AMITRIPTYLINE | 25MG | TABLET | Discontinued | 2025-01-10 | 2025-01-11 | 247466 |
APO-AMITRIPTYLINE | 50MG | TABLET | To be discontinued | 2025-01-10 | 2025-01-27 | 247469 |
APO-AMITRIPTYLINE | 25MG | TABLET | Discontinued | 2019-01-04 | 2019-02-13 | 71351 |
APO-AMITRIPTYLINE | 50MG | TABLET | To be discontinued | 2019-01-04 | 2021-06-05 | 71354 |